Moderna, Inc. (MRNA) said a preclinical study evaluating mRNA-1273, the company's vaccine candidate against COVID-19, showed that a two-dose vaccination schedule of mRNA-1273 led to a robust immune response and protection against SARS-CoV-2 infection in the upper and lower airways in non-human primates, without evidence of vaccine-associated enhanced respiratory disease.
from RTT - Biotech https://ift.tt/2P3vuFt
via IFTTT
No comments:
Post a Comment